スタッフ ログイン
Japanese |
English
ご質問・ご要望
一覧
検索
生物種別閲覧
登録
統計情報
検索
ホーム
一覧
論文
特許
論文 - 一覧
«
»
30 Hits
検索条件 : 絞込み (MeSH = Lung Neoplasms* / drug therapy)
生物種
リソース名
RRC ID
タイトル
ジャーナル
公開日
外部リンク
ヒト・動物細胞
EBC-1(RCB1965)
79442
PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer.
PLoS One
2024-1-1
Pubmed
Full text
ヒト・動物細胞
Ba/F3(RCB0805)
79063
Characterization of
BRAF
Thr599dup
Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling.
JCO Precis Oncol
2024-4-1
Pubmed
Full text
ヒト・動物細胞
LU65(RCB1967)
78707
DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS
G12C
-mutant cancer.
J Biomed Sci
2023-6-29
Pubmed
Full text
ヒト・動物細胞
LK-2(RCB1970)
78706
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
J Thorac Oncol
2023-4-1
Pubmed
Full text
ヒト・動物細胞
Ba/F3-CL1(RCB4474)
78592
Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
J Thorac Oncol
2024-1-1
Pubmed
Full text
ヒト・動物細胞
Ba/F3(RCB0805)
78156
The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics.
Exp Cell Res
2023-3-1
Pubmed
Full text
ヒト・動物細胞
A549(RCB0098)
,
HCT116(RCB2979)
77791
Bisabosqual A: A novel asparagine synthetase inhibitor suppressing the proliferation and migration of human non-small cell lung cancer A549 cells.
Eur J Pharmacol
2023-12-5
Pubmed
Full text
ヒト・動物細胞
EBC-1(RCB1965)
77552
Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer.
J Enzyme Inhib Med Chem
2023-1-1
Pubmed
Full text
ヒト・動物細胞
293T(RCB2202)
76740
Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer.
Cell Cycle
2023-9-1
Pubmed
Full text
ヒト・動物細胞
,
遺伝子材料
II-18(RCB2093)
,
tFucci(CA)2/pCSII-EF (RDB15446)
76706
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
Cell Rep Med
2023-8-3
Pubmed
Full text
実験動物マウス
RBRC09497
75628
Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8
+
T cell cytotoxicity and proliferation.
Sci Adv
2023-5-19
Pubmed
Full text
ヒト・動物細胞
PC-14(RCB0446)
74901
Suppression of non-small-cell lung cancer A549 tumor growth by an mtDNA mutation-targeting pyrrole-imidazole polyamide-triphenylphosphonium and a senolytic drug.
Cancer Sci
2022-4-1
Pubmed
Full text
ヒト・動物細胞
LC-2/ad(RCB0440)
74701
Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.
Biochem Biophys Res Commun
2022-11-19
Pubmed
Full text
ヒト・動物細胞
Lu99(RCB1900)
,
LU65(RCB1967)
74511
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Clin Cancer Res
2022-8-2
Pubmed
Full text
酵母
74180
Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors.
Pharmacol Res
2022-11-1
Pubmed
Full text
ヒト・動物細胞
Ba/F3(RCB0805)
74010
Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Cancer Sci
2022-11-1
Pubmed
Full text
ヒト・動物細胞
II-18(RCB2093)
73644
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers.
Lung Cancer
2023-1-1
Pubmed
Full text
ヒト・動物細胞
PC-9(RCB4455)
,
Jurkat(RCB3052)
73099
A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations.
Nat Commun
2022-11-14
Pubmed
Full text
ヒト・動物細胞
Ba/F3(RCB0805)
,
WEHI-3(RCB0035)
72002
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
J Hematol Oncol
2022-6-11
Pubmed
Full text
ヒト・動物細胞
A549(RCB0098)
71887
A New 1,2-Naphthoquinone Derivative with Anti-lung Cancer Activity.
Chem Pharm Bull (Tokyo)
2022-1-1
Pubmed
Full text